The in vitro effect of sintamil, as a modulator alone and in combination with hydroxyurea (HU), on cytotoxicity was studied in 16 cases of human chronic myeloid leukemia (CML). We investigated the cytotoxicity of the drugs as a function of the exposure dose (HU, 10−4 M; sintamil, 10 μg/ml) and the exposure time (1 h) to the agent. Cytotoxicity was evaluated as the inhibition of incorporation of [3H-methyl]thymidine in the nucleic acids of CML cells. Cytotoxicity of HU was greatly enhanced (P < 0.001) by 1 h exposure of the CML cells to sintamil. The present data indicate that sintamil potentiates the cytotoxic activity of HU in CML cells.
Get full access to this article
View all access options for this article.
References
1.
AdwankarM.K., ChitnisM.P.: Effect of hyperthermia alone and in combination with anticancer drugs on the viability of P388 leukemic cells.Tumori, 70: 231–234, 1984.
2.
AdwankarM.K., ChitnisM.P.: Alteration in natural resistance of sarcoma-180 tumor to bouvardin (NSC 259968) following hyperthermia.Tumori, 69: 309–312, 1983.
3.
BrownF., KleinM., KandaswamyT., MandleH.: Rapid membrane filtration technics for studying the action of 6-thioguanine on tumor cells in vitro.Cancer Res., 23: 254–259, 1963.
4.
ChitnisM.P., MenonR.S., GudeR.P.: Effect of Tween 80 on adriamycin cytotoxicity in murine P388 leukemia.Tumori, 70: 313–315, 1984.
5.
DavidJ., GrewalR.: Pharmacological properties of sintamil. A new antidepressant agent.Ind. J. Exp. Biol., 12: 225–230, 1974.
6.
GailM., BooneC.: Procaine inhibition of fibroblast motility and proliferation.Exp. Cell. Res., 73: 252–255, 1972.
7.
GuptaA., GrewalR.: Profile of a new antidepressant sintamil.Ciba of India Ltd., 1972.
8.
IchihashiH., KandoT., SakakibaraS., AkiyamaS., WatanabeT.: Application of radioactive precursors for the evaluation of sensitivity of cancer cells to anticancer drugs.Oncology, 41: 88–95, 1984.
9.
MedoffJ., MedoffG., GoldsteinM.N., SchlessingerD., KobayashiG.S.: Amphotericin-B induced sensitivity to actinomycin D in drug resistant HeLa-cells.Cancer Res., 35: 2548–2552, 1975.
10.
MenonR., ChitnisM., AdwankarM., BasrurV., AmonkarA.: Tween-80 alters natural resistance of sarcoma-180 to bouvardin (NSC 259968).Tumori, 70: 23–27, 1984.
11.
MizunoS., IshidaA.: Selective enhancement of the cytotoxicity of the bleomycin derivative, peplo-mycin, by local anesthetics alone and combined with hyperthermia.Cancer Res., 42: 4726–4729, 1982.
12.
MizunoS., IshidaA.: Selective enhancement of bleomycin cytotoxicity by local anesthetics. Bio-chem.Biophys. Res. Commun., 105: 425–431, 1982.
13.
MizunoS., IshidaA.: Potentiation of bleomycin cytotoxicity by membrane interacting drugs and increased calcium ions.Biochem. Biophys. Res. Commun., 107: 1021–1027, 1982.
14.
Nguyen-NgocT., VrignaudP., RobertJ.: Cellular pharmacokinetics of doxorubicin in cultured mouse sarcoma cells originating from autochthonous tumors.Oncology, 41: 55–60, 1984.
15.
NicolsonG., SmithJ., PosteG.: Effect of local anesthetics on cell morphology and membrane-associated cytoskeletal organisation in BALB/3T3 cells.J. Cell. Biol., 68: 395–402, 1976.
16.
PapahadjopoulosD.: Studies on the mechanism of action of local anesthetics with phospholipid model membranes.Biochim. Biophys. Acta, 265: 169–186, 1972.
17.
PapahadjopoulosD., JacobsonK., PosteG., ShepherdG.: Effects of local anesthetics on membrane properties. I. Changes in the fluidity of phospholipid bilayers.Biochem. Biophys. Acta, 394: 504–519, 1975.
18.
PosteG., PapahadjopoulosD., JacobsonK., VailW.: Effect of local anesthetics on membrane properties. II. Enhancement of the susceptibility of mammalian cells to agglutination by plant lectines.Biochim. Biophys. Acta, 394: 520–539, 1975.
19.
PradhanS., BasrurV., ChitnisM.: In vitro enhancement of adriamycin cytotoxicity in human myeloid leukemia cell exposed to verapamil.Oncology, 41: 406–408, 1984.
20.
SchwarzmeierJ., PaiettaE., MittermayerK., PirkerR.: Prediction of the response to chemotherapy in acute leukemia by a short term test in vitro.Cancer, 53: 390–395, 1984.
21.
SeemanP.: The membrane actions of anesthetics and tranquilizers.Pharmacol. Rev., 24: 583–655, 1972.
22.
TsuruoT., IidaH., TsukagoshiS., SakuraiY.: Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil.Cancer Res., 41: 1967–1972, 1981.
23.
TsuruoT., IidaH., TsukagoshiS., SakuraiY.: Increased accumulation of vincristine and adriamycin in resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors.Cancer Res., 42: 4730–4733, 1982.
24.
TsuruoT., IidaH., NaganumaK., TsukagoshiS., SakuraiY.: Promotion by verapamil of vincristine responsiveness in tumor cell lines inherently resistant to the drug.Cancer Res., 43: 808–813, 1983.
25.
TsuruoT., IidaH., NojiriM., TsukagoshiS., SakuraiY.: Potentiation of chemotherapeutic effect of vincristine in vincristine resistant tumor bearing mice by calmodulin inhibitor clomipramine.J. Pharm. Dyn., 6: 145–147, 1983.
26.
WeisenthalL.M., MarsdenJ.A., DillP.L., Maca-lusoC.K.: A novel dye exclusion method for testing in vitro chemosensitivity of human tumors.Cancer Res., 43: 749–757, 1983.
27.
WeissB., LevinR.M.: Mechanism of selectively inhibiting the activation of cyclic nucleotide phosphodiesterase and adenylcyclase by antipsychotic agents.Adv. Cyclic Nucleotide Res., 9: 285–303, 1978.
28.
WilkieD.: Antimitochondrial drugs in cancer chemotherapy: Preliminary communication.J. R Soc. Med., 72: 599–601, 1979.
29.
WrightJ.C., WalkerD.: A predictive test for the selection of cancer chemotherapeutic agents for the treatment of human cancer.J. Surg. Oncol., 7: 381–393, 1975.
